Intangible Assets

9 Months Ended

Jun. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Intangible Assets

Intangible assets consisted of:

	June 30, 2019				September 30, 2018
(Millions of dollars)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Amortized intangible assets
Developed technology	$	13,972	$	2,638	$	13,966	$	1,782
Customer relationships	4,610		1,102		4,584		861
Product rights	115		60		121		58
Trademarks	407		97		407		84
Patents and other	433		301		397		288
Amortized intangible assets	$	19,537	$	4,198	$	19,475	$	3,073
Unamortized intangible assets
Acquired in-process research and development (a)	$	1			$	37
Trademarks	2				2
Unamortized intangible assets	$	3			$	39

(a) The decrease in the carrying value of assets at June 30, 2019 primarily reflects a write-down recorded in the third quarter by the Interventional segment's Surgery unit.

Intangible amortization expense for the three months ended June 30, 2019 and 2018 was $378 million and $375 million, respectively. Intangible amortization expense for the nine months ended June 30, 2019 and 2018 was $1,132 million and $879 million, respectively. The increase in intangible amortization expense for the nine months ended June 30, 2019 was attributable to assets acquired in the Bard transaction, which is further discussed in Note 9.

The following is a reconciliation of goodwill by business segment:

(Millions of dollars)	Medical			Life Sciences			Interventional			Total
Goodwill as of September 30, 2018	$	10,054		$	775		$	12,771		$	23,600
Divestiture-related adjustments	—			3			—			3
Purchase accounting adjustments (a)	(15		)	—			(75		)	(90		)
Currency translation	(12		)	(3		)	—			(14		)
Goodwill as of June 30, 2019	$	10,027		$	775		$	12,696		$	23,498

(a)

The purchase accounting adjustments were primarily driven by adjustments to tax-related balances recorded upon the finalization of the Bard acquisition allocation within one year of the transaction's closing.